<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04062539</url>
  </required_header>
  <id_info>
    <org_study_id>INTERCEPT:CEPD</org_study_id>
    <nct_id>NCT04062539</nct_id>
  </id_info>
  <brief_title>Total Cerebral Protection With Embolic Protection Devices Thoracic Aortic Stenting</brief_title>
  <official_title>Total Cerebral Protection With Embolic Protection Devices in Thoracic Aortic Stenting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St Mary's Hospital, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke and silent cerebral infarction are a real risk with thoracic enodvascular aortic
      repair (TEVAR). The investigator propose to prospectively observational study with enrolment
      of all patients undergoing TEVAR for thoracic and thoracoabdominal conditions including
      aneurysmal degeneration, Type B dissection and acute aortic syndromes over a 24 month period,
      equating to a minimum of 20-30 patients per year. Patients undergoing juxtra-renal and
      infra-renal aortic stenting will form a control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TEVAR involves the insertion of a stent into the thoracic aorta to re-line it and prevent
      life-threatening haemorrhage from rupture, and ultimately death. The stent is inserted
      through a small cut in the femoral artery in the groin that is able to track to the desired
      location in the thoracic aorta over wires. The thoracic aorta and the branches it provides to
      supply the brain are diseased with atherosclerotic plaques and thrombus. The manipulation of
      wires and stents over these diseased locations can lead to small fragments breaking off and
      travelling to the brain to block the blood supply to areas of the brain (cerebral
      embolisation).

      Cerebral embolic protection devices (CEPDs) consist of filters that can be placed into the
      branches of the thoracic aorta that supply the brain(supra-aortic branches) before TEVAR and
      can capture and remove solid debris, preventing it from reaching the brain.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Waiting for funding
  </why_stopped>
  <start_date type="Actual">October 4, 2018</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of brain injury assessed by Magnetic resonance imaging (MRI) test</measure>
    <time_frame>Pre-operative and post-operative up to 6 months</time_frame>
    <description>Magnetic resonance imaging (MRI) of the brain is a safe and painless test that uses a magnetic field and radio waves to produce detailed images of the brain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of embolic event</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Transcranial doppler monitoring of embolic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in neurocognition function</measure>
    <time_frame>Pre-operative and post-operative up until 6 months</time_frame>
    <description>Neurocognitive tests to assess the changes in neurocognition function</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Stroke</condition>
  <condition>Silent Cerebral Infarct</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sentinel and Spider</intervention_name>
    <description>Dual filter and single filter</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All captured material from the filters will be analysed and this can include atherosclerotic
      particles and thrombus.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Secondary care; elective patients from an outpatient clinical bases and emergency patients
        presenting through Accident and Emergency
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients requiring TEVAR as decided upon by a multidisciplinary meeting

        Exclusion Criteria:

          -  Contraindication to MRI scanning

          -  Unable to give consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Gibbs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W21NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Perera AH, Rudarakanchana N, Monzon L, Bicknell CD, Modarai B, Kirmi O, Athanasiou T, Hamady M, Gibbs RG. Cerebral embolization, silent cerebral infarction and neurocognitive decline after thoracic endovascular aortic repair. Br J Surg. 2018 Mar;105(4):366-378. doi: 10.1002/bjs.10718. Epub 2018 Feb 12.</citation>
    <PMID>29431856</PMID>
  </reference>
  <reference>
    <citation>Grover G, Perera AH, Hamady M, Rudarakanchana N, Barras CD, Singh A, Davies AH, Gibbs R. Cerebral embolic protection in thoracic endovascular aortic repair. J Vasc Surg. 2018 Dec;68(6):1656-1666. doi: 10.1016/j.jvs.2017.11.098. Epub 2018 May 24.</citation>
    <PMID>29804744</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>cerebral embolic protection device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

